Attendees

TIRmed Pharma
TIR-C is a next-generation proprietary topical medication, for treatment of mild-moderate AD. By early treatment with TIR-C, we aim to prevent disease progression into severe states and the onset of the atopic march. The immunomodulatory, water-based TIR-C cream ameliorates itch/burn. It is involved in upholding a vicious circle of undesirable immune response leading the biggest unresolved AD problem: intense itch.